Indivior and 42 states reach $102 million settlement
Indivior has agreed to pay $102.5 million to settle claims by a coalition of 42 states that it engaged in an illegal product-hopping scheme to prevent generic competition for its opioid treatment Suboxone.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10